Department of Otolaryngology, UT Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-9035, USA.
Expert Rev Clin Immunol. 2010 Mar;6(2):197-204. doi: 10.1586/eci.09.89.
Olopatadine hydrochloride nasal spray (Patanase Nasal Spray, Alcon Laboratories, TX, USA) was approved by the US FDA in 2008, and is indicated for the relief of symptoms of seasonal allergic rhinitis (SAR), also referred to as allergic rhinosinusitis. Olopatadine is an antihistamine with selective H1-receptor antagonist activity. Clinical trials of olopatadine nasal spray have demonstrated safety and efficacy in the treatment of SAR patients. With an onset of action of 30 min, olopatadine nasal spray has also been shown to improve quality of life, ability to perform work and the conduct of usual activities in SAR patients.
盐酸奥洛他定鼻喷雾剂(帕坦塞鼻喷雾剂,爱尔康实验室,德克萨斯州,美国)于 2008 年获得美国食品药品监督管理局批准,用于缓解季节性过敏性鼻炎(SAR)的症状,也称为过敏性鼻-鼻窦炎。盐酸奥洛他定是一种具有选择性 H1 受体拮抗剂活性的抗组胺药。盐酸奥洛他定鼻喷雾剂的临床试验已证明其在治疗 SAR 患者方面的安全性和有效性。奥洛他定鼻喷雾剂起效迅速,可在 30 分钟内起效,还可改善 SAR 患者的生活质量、工作能力和日常活动能力。